Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX®..
Hayward Field
News and Video Search Results
News coverage
-
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
Business Wire
-
Pulse Biosciences Announces Plans to Initiate a Rights Offering
Business Wire
-
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
Business Wire
-
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
Business Wire
0 shares
1 views
You might like
Hayward Field media coverage
Chemours Celebrates Black History Month and HBCUs Role in Helping Create STEM Leaders Now and for the Future
Accesswire
*NORTHAMPTON, MA / ACCESSWIRE / February 27, 2024 / *Black History Month is a time when people in the United States both celebrate..
-
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study
Business Wire
-
Gunderson Direct Goes Platinum and Raises Over $72,000 for Charity
Accesswire
-
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
Business Wire
-
Signature Aviation Closes on Acquisition of Meridian
Business Wire
Advertisement
More coverage
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp
Business Wire
HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company primarily focused on leveraging its novel and..
-
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter
Business Wire
-
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode
Business Wire
-
Pulse Biosciences to Present at the 35th Annual Piper Sandler Healthcare Conference
Business Wire
-
Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results
Business Wire